Free tool
FAERS Monitor: Icotyde
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 220149 or its brand name (Icotyde, Icotrokinra Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
428
Serious
66
15% of reports
Hospitalization
15
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- headache46
- nausea38
- product dose omission issue30
- fatigue27
- rash24
- drug ineffective23
- psoriasis19
- off label use15
- pain15
- diarrhoea14
- cough13
- abdominal discomfort12
- pruritus12
- gastrointestinal disorder9
- arthralgia8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2026 | 428 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,731 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| psoriasisSignal | 19 | 7.1 | 4.6 | 95 |
| product dose omission issueSignal | 30 | 5.0 | 3.6 | 94 |
| gastrointestinal disorderSignal | 9 | 4.9 | 2.6 | 25 |
| headacheSignal | 46 | 3.6 | 2.7 | 87 |
| abdominal discomfortSignal | 12 | 3.5 | 2.0 | 19 |
| rashSignal | 24 | 2.7 | 1.8 | 25 |
| nauseaSignal | 38 | 2.4 | 1.7 | 30 |
| coughSignal | 13 | 2.3 | 1.3 | 8 |
| fatigue | 27 | 1.7 | 1.2 | 7 |
| pruritus | 12 | 1.5 | 0.9 | 2 |
| pain | 15 | 1.2 | 0.7 | 0 |
| diarrhoea | 14 | 1.1 | 0.6 | 0 |
| arthralgia | 8 | 0.9 | 0.5 | 0 |
| drug ineffective | 23 | 0.9 | 0.6 | 0 |
| off label use | 15 | 0.8 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.